[go: up one dir, main page]

NO20031024D0 - Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer - Google Patents

Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer

Info

Publication number
NO20031024D0
NO20031024D0 NO20031024A NO20031024A NO20031024D0 NO 20031024 D0 NO20031024 D0 NO 20031024D0 NO 20031024 A NO20031024 A NO 20031024A NO 20031024 A NO20031024 A NO 20031024A NO 20031024 D0 NO20031024 D0 NO 20031024D0
Authority
NO
Norway
Prior art keywords
glucogenic
phosphorylase inhibitors
amides
amide derivatives
bicyclic
Prior art date
Application number
NO20031024A
Other languages
English (en)
Other versions
NO20031024L (no
Inventor
Julie B Bartlett
Sue Freeman
Peter Kenny
Andrew Morley
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20031024D0 publication Critical patent/NO20031024D0/no
Publication of NO20031024L publication Critical patent/NO20031024L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20031024A 2000-09-06 2003-03-05 Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer NO20031024L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021831.3A GB0021831D0 (en) 2000-09-06 2000-09-06 Chemical compounds
PCT/SE2001/001880 WO2002020530A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
NO20031024D0 true NO20031024D0 (no) 2003-03-05
NO20031024L NO20031024L (no) 2003-03-05

Family

ID=9898927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031024A NO20031024L (no) 2000-09-06 2003-03-05 Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer

Country Status (30)

Country Link
US (1) US20030232875A1 (no)
EP (1) EP1317459B1 (no)
JP (1) JP2004508376A (no)
KR (1) KR100802369B1 (no)
CN (2) CN1896078A (no)
AT (1) ATE263772T1 (no)
AU (2) AU2001282833B2 (no)
BG (1) BG107624A (no)
BR (1) BR0113606A (no)
CA (1) CA2417594A1 (no)
CZ (1) CZ2003616A3 (no)
DE (1) DE60102710T2 (no)
DK (1) DK1317459T3 (no)
EE (1) EE200300083A (no)
ES (1) ES2217183T3 (no)
GB (1) GB0021831D0 (no)
HU (1) HUP0400784A3 (no)
IL (1) IL154291A0 (no)
IS (1) IS2110B (no)
MX (1) MXPA03001512A (no)
NO (1) NO20031024L (no)
NZ (1) NZ524011A (no)
PL (1) PL361024A1 (no)
PT (1) PT1317459E (no)
RU (1) RU2003104013A (no)
SK (1) SK2592003A3 (no)
TR (1) TR200401659T4 (no)
UA (1) UA73781C2 (no)
WO (1) WO2002020530A1 (no)
ZA (1) ZA200301013B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
DK1375477T3 (da) * 2002-06-17 2010-01-25 Saltigo Gmbh Fremgangsmåde til fremstilling af mono-N-sulfonylerede diaminer
ATE443041T1 (de) * 2002-07-11 2009-10-15 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
GB0222912D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
MXPA05004968A (es) 2002-11-07 2005-08-02 Pfizer Prod Inc N-(indol-z-carbonil)amidas como agentes anti-diabeticos.
BRPI0409465A (pt) 2003-04-17 2006-05-02 Pfizer Prod Inc derivados de carboxamida como agentes antidiabéticos
UA84146C2 (ru) * 2003-05-21 2008-09-25 Прозидион Лимитед Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004113345A1 (ja) * 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318463D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318464D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020985A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005020986A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
GB0320422D0 (en) * 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
BRPI0418244A (pt) 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) * 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
PT1819704E (pt) * 2004-12-02 2008-10-06 Prosidion Ltd Derivado amida de ácido pirrolopiridina-2-carboxílico útil como inibidor de glicogénio fosforilase
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
JP2008526999A (ja) * 2005-01-19 2008-07-24 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン
WO2006082400A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Indan-amide derivatives with glycogen phosphorylase inhibitory activity
BRPI0606838A2 (pt) * 2005-02-05 2010-02-09 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
KR101381768B1 (ko) 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008047821A1 (en) * 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
KR101581289B1 (ko) 2007-05-31 2015-12-31 세프라코 아이엔시. 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100152200A1 (en) * 2008-11-17 2010-06-17 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
AU2016287581B2 (en) 2015-07-02 2019-06-06 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
TWI836679B (zh) 2016-02-05 2024-03-21 美商戴納立製藥公司 化合物、組合物及方法
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7398391B2 (ja) 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
TW202115086A (zh) * 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2021106988A1 (ja) * 2019-11-27 2021-06-03 杏林製薬株式会社 Ｇ９ａ阻害剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
ES2081747B1 (es) * 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
JP2002506073A (ja) * 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ プロテイン・チロシン・ホスファターゼ（ＰＴＰａｓｅｓ）のモジュレーター
ES2211454T3 (es) * 1999-09-30 2004-07-16 Pfizer Products Inc. Pirrolilamidas como inhibidores de la colageno fosforilasa.
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use

Also Published As

Publication number Publication date
ES2217183T3 (es) 2004-11-01
TR200401659T4 (tr) 2004-09-21
IS6727A (is) 2003-02-24
ZA200301013B (en) 2004-05-05
BR0113606A (pt) 2003-06-24
WO2002020530A1 (en) 2002-03-14
PT1317459E (pt) 2004-08-31
PL361024A1 (en) 2004-09-20
RU2003104013A (ru) 2004-08-20
EE200300083A (et) 2004-12-15
CA2417594A1 (en) 2002-03-14
MXPA03001512A (es) 2003-06-09
KR100802369B1 (ko) 2008-02-14
ATE263772T1 (de) 2004-04-15
IS2110B (is) 2006-05-15
CN1896078A (zh) 2007-01-17
HUP0400784A3 (en) 2007-09-28
BG107624A (bg) 2004-01-30
GB0021831D0 (en) 2000-10-18
IL154291A0 (en) 2003-09-17
HK1055299A1 (en) 2004-01-02
CN1473163A (zh) 2004-02-04
JP2004508376A (ja) 2004-03-18
CN1264846C (zh) 2006-07-19
HUP0400784A2 (hu) 2004-07-28
KR20030025305A (ko) 2003-03-28
SK2592003A3 (en) 2003-08-05
DK1317459T3 (da) 2004-07-12
US20030232875A1 (en) 2003-12-18
EP1317459A1 (en) 2003-06-11
EP1317459B1 (en) 2004-04-07
AU8283301A (en) 2002-03-22
NZ524011A (en) 2004-08-27
NO20031024L (no) 2003-03-05
UA73781C2 (en) 2005-09-15
DE60102710D1 (de) 2004-05-13
AU2001282833B2 (en) 2006-07-06
CZ2003616A3 (cs) 2003-05-14
DE60102710T2 (de) 2005-04-14

Similar Documents

Publication Publication Date Title
NO20031024L (no) Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
FI950309A0 (fi) Proliiniamidijohdannaisia
CA2336909A1 (en) Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
WO1998028282A3 (en) OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
DE60045508D1 (de) Dalda-analoge und ihre verwendung
EA200400432A1 (ru) Производные мочевины
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2001066564A3 (en) Gamma-secretase inhibitors
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
EP1126836A4 (en) BENZAMIDES AS POTASSIUM CHANNEL INHIBITORS
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
GB9601722D0 (en) Heterocyclic derivatives
NO20052182L (no) Nye forbindelser
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
PT1056754E (pt) Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
TW200510370A (en) Urea derivatives
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
SE9902596D0 (sv) Pharmaceutically active compounds
AU2003214602A1 (en) Derivatives of 1, 3-cyclic propanediol phosphate and their action as cell stimulants

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application